EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury

Serena Omo-Lamai iD, Jia Nong iD, Krupa Savalia, Brian J Kelley, Jichuan Wu, Sahily Esteves-Reyes, Liam S Chase iD, Vladimir R Muzykantov, Oscar A Marcos-Contreras, Jean-Pierre Dollé, Douglas H Smith, Jacob S Brenner

PLOS ONE · 2024

DOI: 10.1371/journal.pone.0297451 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2024. Verfasst von Serena Omo-Lamai und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, United States of Am…. Hauptthemen laut MEDLINE: Brain Injuries, Traumatic, Vascular Cell Adhesion Molecule-1, Blood-Brain Barrier, Nanoparticles. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAID NIH HHS, NINDS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Traumatic brain injury has faced numerous challenges in drug development, primarily due to the difficulty of effectively delivering drugs to the brain. However, there is a potential solution in targeted drug delivery methods involving antibody-drug conjugates or nanocarriers conjugated with targeting antibodies. Following a TBI, the blood-brain barrier (BBB) becomes permeable, which can last for years and allow the leakage of harmful plasma proteins. Consequently, an appealing approach for TBI treatment involves using drug delivery systems that utilize targeting antibodies and nanocarriers to help restore BBB integrity. In our investigation of this strategy, we examined the efficacy of free antibodies and nanocarriers targeting a specific endothelial surface marker called vascular cell adhesion molecule-1 (VCAM-1), which is known to be upregulated during inflammation. In a mouse model of TBI utilizing central fluid percussion injury, free VCAM-1 antibody did not demonstrate superior targeting when comparing sham vs. TBI brain. However, the administration of VCAM-1-targeted nanocarriers (liposomes) exhibited a 10-fold higher targeting specificity in TBI brain than in sham control. Flow cytometry and confocal microscopy analysis confirmed that VCAM-1 liposomes were primarily taken up by brain endothelial cells post-TBI. Consequently, VCAM-1 liposomes represent a promising platform for the targeted delivery of therapeutics to the brain following traumatic brain injury.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain Injuries, TraumaticVascular Cell Adhesion Molecule-1Blood-Brain BarrierNanoparticlesAnimalsMiceLiposomesMaleDrug Delivery SystemsMice, Inbred C57BLDisease Models, AnimalEndothelial Cells

Substanzen

Vascular Cell Adhesion Molecule-1Liposomes

Autor:innen und Institutionen

  • Department of Bioengineering, School of Engineering and Applied Sciences, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Departments of Neurology & Neurological Surgery, University of California-Davis, Sacramento, California, United States of America.
  • Department of Neurosurgery, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Department of Medicine, Division of Pulmonary Allergy and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
  • Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.

ORCID-Profile: Serena Omo-Lamai, Jia Nong, Liam S Chase

Förderung

  • NHLBI NIH HHS
  • NIAID NIH HHS
  • NINDS NIH HHS
  • American Heart Association
  • National Institutes of Health
  • Cardiovascular Institute of the University of Pennsylvania
  • Paul G. Allen Family Foundation

Zitieren

APA

Omo-Lamai, S., Nong, J., Savalia, K., Kelley, B. J., Wu, J., Esteves-Reyes, S., Chase, L. S., Muzykantov, V. R., Marcos-Contreras, O. A., Dollé, J. P., Smith, D. H., & Brenner, J. S. (2024). Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury. PLOS ONE. https://doi.org/10.1371/journal.pone.0297451

Vancouver

Omo-Lamai S, Nong J, Savalia K, Kelley BJ, Wu J, Esteves-Reyes S, et al. Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury. PLOS ONE. 2024. doi:10.1371/journal.pone.0297451

BibTeX
@article{OmoLamai2024,
  author = {Omo-Lamai, Serena and Nong, Jia and Savalia, Krupa and Kelley, Brian J and Wu, Jichuan and Esteves-Reyes, Sahily and Chase, Liam S and Muzykantov, Vladimir R and Marcos-Contreras, Oscar A and Dollé, Jean-Pierre and Smith, Douglas H and Brenner, Jacob S},
  title = {Targeting of nanoparticles to the cerebral vasculature after traumatic brain injury},
  journal = {PLOS ONE},
  year = {2024},
  doi = {10.1371/journal.pone.0297451}
}
Kostenlos starten →